BIEL Upgraded to OTCID — The Old Book Is CLOSED. The New BIEL Story Is a BLOCKBUSTER.
1. The 2024–2025 Financials Are IRRELEVANT — Totally Meaningless — and OTCID Just Proved It
The old numbers? Who cares.
Yes, revenue went from $496,032 to $510,623 and COGS dropped from $132,633 to $77,276 — very nice, very cute numbers for the old BIEL .
But those numbers belong to the prehistoric era — before Electrome, before Haleon, before Veterinary AI. They’re from the dead model, the “standalone device seller” days.
And now BIEL is upgraded to OTCID, which means:
Verified disclosures
Real transparency
Real oversight
Real legitimacy
OTCID is the market saying:
“The old financials don’t matter. This is a NEW company now.”
Because BIEL is no longer a gadget company — it’s the exclusive hardware engine for an AI‑native therapeutics ecosystem across human, veterinary, and global consumer health .
Electrome AI is the brain.
BIEL PEMF is the engine.
Intel Inside — but for pain, recovery, and performance.
The pivot just happened.
The old revenue is totally meaningless now.
2. The OEM Future Is MASSIVE — We’re Talking Millions, Not Pennies
Three OEM engines.
Three multi‑million‑dollar verticals.
All rolling out NOW — not in 2035.
OEM Engine #1 — Electrome (Human Health)
$0.75M–$2.25M early
$4M–$7M expansion
$7.5M–$22M national rollout
OEM Engine #2 — Veterinary AI
$500K–$1.2M elite animals
$3M–$7.5M specialty clinics
$12M–$25M+ global pet wearables
OEM Engine #3 — Haleon (Global Consumer Health)
$2M–$5M pilots
$15M–$35M rollout
$50M–$100M+ mass‑market wearables
Compared to this? The 2024–2025 financials are rounding errors.
OTCID makes these numbers even more powerful because now institutions, brokers, and OEM partners can take BIEL seriously.
3. Capital Factory Validation — The Big Leagues Only
Electrome is backed by Capital Factory, one of the most respected VC groups in the U.S.
Their involvement means:
The tech is real
The platform is scalable
BIEL is locked in as the hardware engine
Microcaps NEVER get this kind of validation.
BIEL did.
Once institutional validation enters the picture, the old micro‑revenues are irrelevant — future cash flows matter now.
OTCID reinforces this.
It’s the “grown‑up table.”
And BIEL just got a seat.
4. The Float, Momentum, and AI Narrative Are a Powder Keg — OTCID Just Lit the Fuse:
A 400% run from .0001 to .0005
A vanishing float
A pending supply squeeze
This is EXACTLY what happens before microcaps explode. And the AI narrative? Electrome turns BIEL into a hot‑sector AI hardware play. The market prices the future, not the past.
OTCID amplifies all of this:
More brokers allow buying
More investors gain access
More liquidity
More demand
Same tiny float
Boom.
5. Profitability Is Close — And the Model Is Lean, Lean, LEAN
BIEL already proved profitability:
Q3 2021 profit: $22,381 on $414,700 revenue
COGS is now dramatically lower.
OEM volumes are rising.
Profitability is right there.
And the $40M tax loss carryforward? That’s a rocket booster for net profit conversion.
OTCID makes all of this more visible, more credible, more investable.
6. PPS Re‑Rating Scenarios — The Old Numbers Don’t Matter
PPS Projections corresponding to hitting milestones:
.001 — Technical breakout
.01 — Cash‑flow positive (est. $1.5M revenue)
.04 — $1M profit
.10 — $2.5M profit (est. $3M revenue, P/E 1000)
$1.00 — After debt payoff + buyback
These valuations are based on future OEM profit, not legacy device sales.
OTCID makes these targets more realistic because:
More buyers
More legitimacy
Higher multiples
Better visibility
7. The Old Story Is Over — The New One Is a Monster
The old financials don’t define BIEL — they’re the last pages of the old story.
The new story is:
AI‑native therapeutics
Multi‑industry OEM dominance
VC validation
Global consumer health
Veterinary expansion
Recurring hardware nodes
A closed‑loop ecosystem
BIEL is no longer a $500K company — it’s a future $100M+ OEM engine.
The past is irrelevant. The future is asymmetric!
8. The “Startup Without Startup Risk”
Five FDA clearances
Validated manufacturing
VC backing
No burn rate
No R&D drag
No regulatory uncertainty
Instead of spending $50M–$100M on development and trials, BIEL already has it all — plus patents pending, including vagus nerve modulation .
This is the rare microcap with:
A regulatory moat
An IP pipeline
A VC‑funded commercialization engine
BEFORE revenue inflection even begins
OTCID makes this narrative even stronger.
CONCLUSION
BIEL just got upgraded to OTCID.
That means the market sees what the bashers don’t:
This is NOT the old BIEL.
This is a NEW company with REAL partners, REAL OEM engines, REAL AI integration, REAL VC backing, and REAL scale ahead.
The old book is closed. The new book is a bestseller.
And the people who don’t get it?
They’re going to get left behind. BYE BYE! (or BUY BUY?)
1. The 2024–2025 Financials Are IRRELEVANT — Totally Meaningless — and OTCID Just Proved It
The old numbers? Who cares.
Yes, revenue went from $496,032 to $510,623 and COGS dropped from $132,633 to $77,276 — very nice, very cute numbers for the old BIEL .
But those numbers belong to the prehistoric era — before Electrome, before Haleon, before Veterinary AI. They’re from the dead model, the “standalone device seller” days.
And now BIEL is upgraded to OTCID, which means:
Verified disclosures
Real transparency
Real oversight
Real legitimacy
OTCID is the market saying:
“The old financials don’t matter. This is a NEW company now.”
Because BIEL is no longer a gadget company — it’s the exclusive hardware engine for an AI‑native therapeutics ecosystem across human, veterinary, and global consumer health .
Electrome AI is the brain.
BIEL PEMF is the engine.
Intel Inside — but for pain, recovery, and performance.
The pivot just happened.
The old revenue is totally meaningless now.
2. The OEM Future Is MASSIVE — We’re Talking Millions, Not Pennies
Three OEM engines.
Three multi‑million‑dollar verticals.
All rolling out NOW — not in 2035.
OEM Engine #1 — Electrome (Human Health)
$0.75M–$2.25M early
$4M–$7M expansion
$7.5M–$22M national rollout
OEM Engine #2 — Veterinary AI
$500K–$1.2M elite animals
$3M–$7.5M specialty clinics
$12M–$25M+ global pet wearables
OEM Engine #3 — Haleon (Global Consumer Health)
$2M–$5M pilots
$15M–$35M rollout
$50M–$100M+ mass‑market wearables
Compared to this? The 2024–2025 financials are rounding errors.
OTCID makes these numbers even more powerful because now institutions, brokers, and OEM partners can take BIEL seriously.
3. Capital Factory Validation — The Big Leagues Only
Electrome is backed by Capital Factory, one of the most respected VC groups in the U.S.
Their involvement means:
The tech is real
The platform is scalable
BIEL is locked in as the hardware engine
Microcaps NEVER get this kind of validation.
BIEL did.
Once institutional validation enters the picture, the old micro‑revenues are irrelevant — future cash flows matter now.
OTCID reinforces this.
It’s the “grown‑up table.”
And BIEL just got a seat.
4. The Float, Momentum, and AI Narrative Are a Powder Keg — OTCID Just Lit the Fuse:
A 400% run from .0001 to .0005
A vanishing float
A pending supply squeeze
This is EXACTLY what happens before microcaps explode. And the AI narrative? Electrome turns BIEL into a hot‑sector AI hardware play. The market prices the future, not the past.
OTCID amplifies all of this:
More brokers allow buying
More investors gain access
More liquidity
More demand
Same tiny float
Boom.
5. Profitability Is Close — And the Model Is Lean, Lean, LEAN
BIEL already proved profitability:
Q3 2021 profit: $22,381 on $414,700 revenue
COGS is now dramatically lower.
OEM volumes are rising.
Profitability is right there.
And the $40M tax loss carryforward? That’s a rocket booster for net profit conversion.
OTCID makes all of this more visible, more credible, more investable.
6. PPS Re‑Rating Scenarios — The Old Numbers Don’t Matter
PPS Projections corresponding to hitting milestones:
.001 — Technical breakout
.01 — Cash‑flow positive (est. $1.5M revenue)
.04 — $1M profit
.10 — $2.5M profit (est. $3M revenue, P/E 1000)
$1.00 — After debt payoff + buyback
These valuations are based on future OEM profit, not legacy device sales.
OTCID makes these targets more realistic because:
More buyers
More legitimacy
Higher multiples
Better visibility
7. The Old Story Is Over — The New One Is a Monster
The old financials don’t define BIEL — they’re the last pages of the old story.
The new story is:
AI‑native therapeutics
Multi‑industry OEM dominance
VC validation
Global consumer health
Veterinary expansion
Recurring hardware nodes
A closed‑loop ecosystem
BIEL is no longer a $500K company — it’s a future $100M+ OEM engine.
The past is irrelevant. The future is asymmetric!
8. The “Startup Without Startup Risk”
Five FDA clearances
Validated manufacturing
VC backing
No burn rate
No R&D drag
No regulatory uncertainty
Instead of spending $50M–$100M on development and trials, BIEL already has it all — plus patents pending, including vagus nerve modulation .
This is the rare microcap with:
A regulatory moat
An IP pipeline
A VC‑funded commercialization engine
BEFORE revenue inflection even begins
OTCID makes this narrative even stronger.
CONCLUSION
BIEL just got upgraded to OTCID.
That means the market sees what the bashers don’t:
This is NOT the old BIEL.
This is a NEW company with REAL partners, REAL OEM engines, REAL AI integration, REAL VC backing, and REAL scale ahead.
The old book is closed. The new book is a bestseller.
And the people who don’t get it?
They’re going to get left behind. BYE BYE! (or BUY BUY?)
1
